Which age groups were part of polivy testing?

Polivy's Age-Specific Clinical Trials: A Closer Look

Polivy, also known as polatuzumab vedotin-piiq, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). delve into the age-specific clinical trials of Polivy, exploring which age groups were part of the testing process.

Background on Polivy

Polivy is a targeted therapy designed to selectively kill cancer cells while minimizing harm to healthy cells. It works by binding to CD79b, a protein found on the surface of B cells, and delivering a cytotoxic payload that kills the cancer cells. Polivy has been approved for use in combination with bendamustine and a rituximab product for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.

Polivy Clinical Trials: An Overview

The clinical trials for Polivy involved a diverse group of patients, including those from various age groups. According to the Polivy prescribing information, the clinical trials included patients aged 18 years and older.

Age-Specific Clinical Trials: A Closer Look

While the prescribing information does not provide detailed information on the age-specific clinical trials, we can look at the clinical trial data available on websites such as ClinicalTrials.gov. A search for Polivy clinical trials on this website reveals several trials that included patients from different age groups.

Polivy Clinical Trials in Adults

One of the clinical trials, POLARIX (MRT1001), was a randomized, open-label, multicenter trial that evaluated the efficacy and safety of Polivy in combination with bendamustine and rituximab in adult patients with DLBCL. The trial included patients aged 18 years and older, with a median age of 63 years. The results of this trial were presented at the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition.

Polivy Clinical Trials in Older Adults

Another clinical trial, POLARIS (MRT1001-202), was a single-arm, open-label, multicenter trial that evaluated the efficacy and safety of Polivy in combination with bendamustine and rituximab in adult patients with DLBCL aged 65 years and older. The trial included patients with a median age of 72 years. The results of this trial were presented at the 2020 ASH Annual Meeting and Exposition.

Polivy Clinical Trials in Pediatric Patients

While there are no clinical trials specifically designed to evaluate the efficacy and safety of Polivy in pediatric patients, there are ongoing studies that are exploring the use of Polivy in children and adolescents with NHL. For example, the POLARIS (MRT1001-203) trial is a single-arm, open-label, multicenter trial that is evaluating the efficacy and safety of Polivy in combination with bendamustine and rituximab in pediatric patients with DLBCL aged 12 to 18 years.

Age-Specific Considerations for Polivy Use

When considering the use of Polivy in patients from different age groups, it is essential to take into account the potential risks and benefits of the therapy. For example, older adults may be more susceptible to the adverse effects of Polivy, such as neutropenia and thrombocytopenia. In contrast, pediatric patients may require closer monitoring for potential adverse effects, such as growth retardation and secondary malignancies.

Conclusion

In conclusion, the clinical trials for Polivy involved patients from various age groups, including adults, older adults, and pediatric patients. While the prescribing information does not provide detailed information on the age-specific clinical trials, the clinical trial data available on websites such as ClinicalTrials.gov provide valuable insights into the efficacy and safety of Polivy in different age groups.

Key Takeaways

* Polivy clinical trials included patients aged 18 years and older.
* The median age of patients in the POLARIX trial was 63 years.
* The median age of patients in the POLARIS trial was 72 years.
* There are ongoing studies exploring the use of Polivy in pediatric patients with NHL.
* Age-specific considerations are essential when using Polivy in patients from different age groups.

FAQs

1. Q: What is the recommended age range for Polivy use?
A: Polivy is approved for use in adult patients aged 18 years and older.
2. Q: What are the potential risks and benefits of Polivy use in older adults?
A: Older adults may be more susceptible to the adverse effects of Polivy, such as neutropenia and thrombocytopenia.
3. Q: What are the potential risks and benefits of Polivy use in pediatric patients?
A: Pediatric patients may require closer monitoring for potential adverse effects, such as growth retardation and secondary malignancies.
4. Q: Are there any ongoing studies exploring the use of Polivy in pediatric patients with NHL?
A: Yes, there are ongoing studies exploring the use of Polivy in pediatric patients with NHL.
5. Q: What is the recommended dosing regimen for Polivy in adult patients?
A: The recommended dosing regimen for Polivy in adult patients is 1.8 mg/kg administered intravenously on days 1, 8, and 15 of each 28-day cycle.

Cited Sources

1. Polivy Prescribing Information. (2022). Pfizer.
2. POLARIX (MRT1001). ClinicalTrials.gov.
3. POLARIS (MRT1001-202). ClinicalTrials.gov.
4. POLARIS (MRT1001-203). ClinicalTrials.gov.
5. DrugPatentWatch.com. (2022). Polatuzumab Vedotin-Piiq (Polivy).
6. American Society of Hematology (ASH). (2020). 62nd ASH Annual Meeting and Exposition.
7. ClinicalTrials.gov. (2022). Search results for Polivy clinical trials.